2 results
Approved WMOPending
The objective of this study is to assess the safety and efficacy of the Veniti Vici* Venous Stent System in achieving patency of the target venous lesion through 36 months in patients who present with clinically significant chronic non-malignant…
Approved WMORecruiting
The anti-TIM-3 monoclonal antibody MBG453 is a novel immunotherapeutic agent with promising activity seen in AML and MDS. The purpose of the current study is to assess clinical effects of MBG453 in combination with azacitidine in adult subjects with…